Publications

Below you find a selection of our key papers.

Key publications Bacteria & Complement

Soluble MAC is primarily released from MAC-resistant bacteria that potently convert complement component C5 Doorduijn DJ, Lukassen MV, van 't Wout MFL, Franc V, Ruyken M, Bardoel BW, Heck AJR, Rooijakkers SHM. Elife, 2022, Aug 10:11:e77503
Bacterial killing by complement requires membrane attack complex formation via surface-bound C5 convertases. Heesterbeek DAC, Bardoel BW, Parsons ES, Bennett I, Ruyken M, Doorduijn DJ, Gorham Jr. RD, Berends ETM, Pyne ALB, Hoogenboom BW, Rooijakkers SHM. EMBO Journal, 2019, Feb 15;38(4).
Complement-dependent outer membrane perturbation sensitizes Gram-negative bacteria to Gram-positive specific antibiotics. Heesterbeek DAC, Martin NI, Velthuizen A, Duijst M, Ruyken M, Wubbolts R, Rooijakkers SHM, Bardoel BW. Sci Rep, 2019, Feb 28;9(1):3074.
Molecular insights into the surface-specific arrangement of complement C5 convertase enzymes. Berends ET, Gorham RD Jr, Ruyken M, Soppe JA, Orhan H, Aerts PC, de Haas CJ, Gros P, Rooijakkers SHM. BMC Biology, 2015, Nov 9;13:934.

Key publications Antibody therapies

Agnostic B cell selection approach identifies antibodies against K. pneumoniae that synergistically drive complement activation. van der Lans, S.P.A., Bardoel, B.W., Ruyken, M., De Haas, C.J.C., Baijens, S., Muts R.M., Scheepmaker L.M., Aerts P.C., van ‘t Wout M.F.L., Preiner J., Marijnissen R.J., Schuurman J., Beurskens F.J., Kerkman P.F., Rooijakkers S.H.M. Nat Commun 15, 8100 (2024).
Antibodies and methods of use thereof in treatment of bacteria Kuipers A, Kessel K, Beurskens,Kessel, De Jong, Strumane, Schuurman J, Parren P, Van Strijp J, Rooijakkers SHM. Granted patent, 2017, WO17198731.
Staphylococcal protein A inhibits complement activation by interfering with IgG hexamer formation. Cruz AR, den Boer MA, Strasser J, Zwarthoff SA, Beurskens FJ, de Haas CJC, Aerts PC, Wang G, de Jong RN, Bagnoli F, van Strijp JAG, van Kessel KPM, Schuurman J, Preiner J, Heck AJR, Rooijakkers SHM. PNAS, 2021, Feb 16; 118(7).
C1q binding to surface-bound IgG is stabilized by C1r2s2 proteases. Zwarthoff SA Widmer K, Kuipers A, Strasser J, Ruyken M, Aerts P, De Haas C, Ugurlar D, den Boer M, Vidarsson G, van Strijp J, Gros P, Parren P, Van Kessel K, Preiner J, Beurskens F, Schuurman J, Ricklin D, Rooijakkers SHM. PNAS, 2021, Jun 29;118(26).
Human monoclonal antibodies against Staphylococcus aureus surface antigens recognize in vitro and in vivo biofilm De Vor L, Van Dijk B, van Kessel K, Kavanaugh J, Haas C, Aerts P, Boel E, Fluit A, Kwiecinski, Krijger G, Ramakers R, Beekman F, Dadachova E, Lam M, Vogely C, van der Wal B, van Strijp J, Horswill A, Weinans H, Rooijakkers SHM. elife, 2022, Jan 6;11:e67301.

Key publications Complement inhibitors & nanobodies

Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. Rooijakkers SHM, Wu J, Ruyken M, van Domselaar R, Planken, Tzekou, Ricklin D, Lambris JD, Janssen BJ, van Strijp JA, Gros P. Nature Immunology, 2009, Jul;10(7):721-7.
Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases Rooijakkers SHM, Ruyken M, Roos A, Daha MR, Presanis J, Sim R, Van Wamel WJB, Van Kessel KP, Van Strijp JAG. Nature Immunology, 2005, Sep 6(9): 920-927.
Inhibition of cleavage of human complement component C5 and the R885H C5 variant by two distinct high affinity anti-C5 nanobodies Eva M. Struijf, Karla I. De la O Becerra, Maartje Ruyken, Carla J.C. de Haas, Fleur van Oosterom, Danique Y. Siere, Joanne E. van Keulen, Dani A.C. Heesterbeek, Edward Dolk, Raimond Heukers, Bart W. Bardoel, Piet Gros, Suzan H.M. Rooijakkers JBC Journal of Biological Chemistry